From the early days of antiretroviral (ARV) monotherapy, to the mid 1990’s when triple therapy (HAART) was discovered to be not only more effective but less toxic, there has been ongoing work to change the face of HIV treatment. Standard of care for HIV treatment requires the combination of NRTI, NNRTI, protease inhibitors, and integrase strand transfer inhibitors. The current challenges with antiretroviral therapy (ART) are pill burden, toxicity and drug-resistance. Newer NRTIs such as abacavir, tenofovir, lamivudine and emtricitabine are now associated with lesser occurrence of mitochondrial toxicity. The landscape of ART is constantly changing and to equip us with all the latest updates, Dr. N Kumarasamy joins us LIVE on Medflix!

HAART : Current & Future 

Human immunodeficiency virus infection has grown to pandemic proportions since the first AIDS cases were reported in 1981. Forty years later, advances in research have resulted in the approval of more than 30 antiretroviral medications, and combination therapy have transformed HIV infection into a chronic but manageable condition. Efforts to improve current therapies focus on treatment simplification and the development of long-acting drugs for treatment and pre-exposure prophylaxis. Join us LIVE for this intriguing session as Dr. Kumarasamy provides an overview on currently available anti-HIV drugs and the latest developments in antiretroviral therapy.

Recent Updates in ART

Chief and Director, VHS-Infectious Diseases Medical Centre | Director, Chennai Antiviral Research and Treatment Clinical Research Site | Head of Department, VHS COVID19 Treatment and Vaccination Centre.

Dr. N Kumarasamy

2

579

11.3k

4.7

Sessions Taken

396

4.8

347

4.6